Skip to main content

Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study

Publication ,  Conference
Lancet, JE; Ravandi, F; Ritchie, EK; Sayar, H; Strickland, SA; Schiller, GJ; Vey, N; Erba, HP; Pigneux, A; Horst, H-A; Recher, C; Odenike, O ...
Published in: BLOOD
December 3, 2015

Duke Scholars

Published In

BLOOD

EISSN

1528-0020

ISSN

0006-4971

Publication Date

December 3, 2015

Volume

126

Issue

23

Location

Orlando, FL

Publisher

AMER SOC HEMATOLOGY

Conference Name

57th Annual Meeting of the American-Society-of-Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lancet, J. E., Ravandi, F., Ritchie, E. K., Sayar, H., Strickland, S. A., Schiller, G. J., … Stuart, R. K. (2015). Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study. In BLOOD (Vol. 126). Orlando, FL: AMER SOC HEMATOLOGY.
Lancet, Jeffrey E., Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Stephen A. Strickland, Gary J. Schiller, Norbert Vey, et al. “Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study.” In BLOOD, Vol. 126. AMER SOC HEMATOLOGY, 2015.
Lancet JE, Ravandi F, Ritchie EK, Sayar H, Strickland SA, Schiller GJ, Vey N, Erba HP, Pigneux A, Horst H-A, Recher C, Odenike O, Carella A-M, Selleslag D, Kell J, Krug U, Page L, DeVault A, Hwang S, Craig AR, Stuart RK. Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study. BLOOD. AMER SOC HEMATOLOGY; 2015.

Published In

BLOOD

EISSN

1528-0020

ISSN

0006-4971

Publication Date

December 3, 2015

Volume

126

Issue

23

Location

Orlando, FL

Publisher

AMER SOC HEMATOLOGY

Conference Name

57th Annual Meeting of the American-Society-of-Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology